Research

Research

Evaluating Progress in Health Care


PMC studies how personalized medicine is reshaping the health care landscape with attention to the emergence of new tests and treatments as well as the policies and practices that influence whether personalized health care strategies are utilized in clinical settings. By advancing a more comprehensive understanding of the utilization of genomic testing as related to coverage and by highlighting the circumstances in which current clinical guidelines and U.S. Food and Drug Administration-approved drug labels support the use of pharmacogenomic strategies, its latest work in this area promises to inform stakeholders as they look to advance the use of personalized medicine.


2021




Personalized Medicine at FDA:
The Scope & Significance of
Progress in 2020






Pharmacogenomics in Clinical Guidelines and at FDA

2020




Personalized Medicine at FDA:
The Scope & Significance of
Progress in 2019






Understanding Genomic Testing Utilization and Coverage in the US




The Personalized Medicine Report: Opportunity, Challenges, and the Future (Sixth Edition)


2019




Personalized Medicine at FDA:
A Progress & Outlook Report






The Evolution of Biomarker Use in Clinical Trials for Cancer Treatments: Key Findings and Implications

2018




Personalized Medicine at FDA: 2017 Progress Report


2017




Personalized Medicine at FDA:
2016 Progress Report






The Personalized Medicine Report: Opportunity, Challenges, and the Future (Fifth Edition)

2015




Biopharmaceutical Companies’ Personalized Medicine Research Yields Innovative Treatments for Patients


Research Lead


Daryl Pritchard, Ph.D., Senior Vice President, Science Policy


Research Assistant


Lindsay Stephens, Program Manager & Secretary to the Board